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Iron excess is closely associated with tumorigenesis
in multiple types of human cancers, with underlying
mechanisms yet unclear. Recently, iron deprivation
has emerged as a major strategy for chemotherapy,
but it exerts tumor suppression only on select human
malignancies. Here, we report that the tumor sup-
pressor protein p53 is downregulated during iron
excess. Strikingly, the iron polyporphyrin heme binds
to p53 protein, interferes with p53-DNA interactions,
and triggers both nuclear export and cytosolic
degradation of p53. Moreover, in a tumorigenicity
assay, iron deprivation suppressed wild-type p53-
dependent tumor growth, suggesting that upregula-
tion of wild-type p53 signaling underlies the selective
efficacy of iron deprivation. Our findings thus identify
a direct link between iron/heme homeostasis and the
regulation of p53 signaling, which not only provides
mechanistic insights into iron-excess-associated
tumorigenesis butmay also help predict and improve
outcomes in iron-deprivation-based chemotherapy.
INTRODUCTION
Iron is essential for cell survival, proliferation, and metabolism, a
fact highlighted by the association of dysregulated iron meta-
bolism with a myriad of human disorders including cancer and
diabetes (Andrews, 2008; Fleming and Ponka, 2012; Rouault,180 Cell Reports 7, 180–193, April 10, 2014 ª2014 The Authors2005; Simcox and McClain, 2013). In particular, decades of
epidemiological and experimental studies have established
that iron excess, due to either genetic factors or excessive
dietary intake, is implicated in multiple types of human cancers
(Torti and Torti, 2013; Toyokuni, 2009). Hereditary hemochroma-
tosis (HH) is a genetic disorder of iron overload, with clinical com-
plications including liver cirrhosis and a 20- to 200-fold increased
risk for hepatocellular carcinoma (Elmberg et al., 2003; Niederau
et al., 1985) or other cancer types (Osborne et al., 2010; Pietran-
gelo, 2010; Radulescu et al., 2012). Meanwhile, tumors repro-
gram iron metabolism to achieve a growth advantage or
metastasis, resulting in the emergence of iron deprivation, via
iron chelation or application of transferrin receptor-neutralizing
antibodies, as a major chemotherapeutic strategy. However,
preclinic and clinical studies have demonstrated that iron depri-
vation only suppresses select human malignancies while having
no effect on other cancer types, with underlying mechanisms of
the selectivity yet elusive (Buss et al., 2004; Yamasaki et al.,
2011). Therefore, a thorough interrogation of the mechanisms
of how iron excess contributes to tumorigenesis and the
molecular basis of the selective efficacy of iron deprivation
would not only further our understanding of cancer biology but
also improve the design of targeted chemotherapy for better
clinical outcomes.
Heme is an iron polyporphyrin that constitutes the prosthetic
group for proteins functioning in a myriad of fundamental
biological processes, including respiration, energetic homeo-
stasis, signal transduction, xenobiotic detoxification, iron meta-
bolism, mRNA processing, and control of circadian rhythm
(Boon et al., 2005; Dioum et al., 2002; Faller et al., 2007; Gilles-
Gonzalez and Gonzalez, 2005; Hu et al., 2008; Ishikawa et al.,
2005; Rajagopal et al., 2008; Yang et al., 2010). The switch
between ferrous (Fe2+) and ferric (Fe3+) states of iron in the
metallo-polyporphyrin, termed as heme and hemin, respectively,
underlies its unique roles in transducing redox and gas signaling
in vivo. Hemewas identified as a ligand for transcriptional factors
such as NPAS2 (Dioum et al., 2002), E75 (Reinking et al., 2005),
and Rev-erb a (Yin et al., 2007), where hemewas shown to play a
regulatory role by modulating the respective protein functional-
ities. We have also found that arginyl-tRNA protein transferase
(Ate1), a key component of the N-end rule pathway in the
ubiquitin (Ub)-proteasome system, binds to heme and allows
the N-end rule pathway to act as a sensor of heme and redox
state (Hu et al., 2005, 2008; Kwon et al., 2002; Varshavsky,
2012). Because heme is identified as a prosthetic group in an
expanding body of proteins in multiple pathophysiological pro-
cesses, it is conceivable that we might be still at an early stage
in understanding the regulatory roles of heme.
Tumor suppressor p53 suppresses tumorigenesis and
regulates DNA-damage repair, cell-cycle arrest, and tumor
responses to chemotherapy (Baker et al., 1989; Espinosa
et al., 2003; Kastan et al., 1991; Liu et al., 2011; Vogelstein
et al., 2000; Vousden and Prives, 2009). Recent work also iden-
tified p53 as a cellular hub in regulating and responding to cell
metabolism (Jiang et al., 2013; Maddocks and Vousden, 2011).
p53 protein is also a major regulator of cellular responses to
redox signaling. Thus far, a few small molecules, such as
NAD+ and ADP, have been identified as physiological ligands
for p53 protein, modulating the transcription of a set of p53 target
genes in response to changes in cell redox state and energy
metabolism (McLure et al., 2004).
It is yet unknown whether p53 might bind to any other cellular
small molecules, either metabolites or signaling messengers,
and directly sense cellular redox signaling. Given the prominent
roles of tumor suppressor p53 in regulating tumorigenesis and
cellular responses to genotoxic stresses, we set out to examine
whether and how iron excessmight affect p53 signaling and thus
contribute to tumorigenesis associated with iron overload.
We also used cell and animal models to investigate the
molecular determinants underlying the selective efficacy of iron
deprivation-based chemotherapy.
RESULTS
Tumor Suppressor p53 Protein Is Downregulated during
Iron Excess
Patients with HH have defects in the control of iron entry into
circulation, which allows for the toxic accumulation of iron in
parenchymal cells of vital organs (Pietrangelo, 2010; Weiss,
2010). The known genetic factors for human HH are mutations
in the genes encoding the human hemochromatosis protein
(Hfe), transferrin receptor 2 (Tfr2), hemojuvelin (Hjv), ferroportin
(Fpn), and more rarely hepcidin (Hamp). It was estimated that
10% of the white population worldwide carries disease-associ-
ated mutations in Hfe, with disease penetrance of 2%–38%
among male and 1%–10% among female carriers (Fleming
and Ponka, 2012). A 20- to 200-fold higher risk for hepatocellular
carcinoma or many other types of cancer was reported for
patients with hemochromatosis with iron overload, highlightinga strong association between increased iron metabolism and
human malignancy (Torti and Torti, 2013). However, the
underlying mechanism remains unclear.
Mice with homozygous deletion of the human hemochroma-
tosis (Hfe) gene (Hfe/) faithfully recapitulate most human HH
symptoms, including significant liver iron overload as assessed
by Perls’ Prussian Blue staining (Zhou et al., 1998) (Figure 1A).
Using a 3,30,5,50-tetramethylbenzidine (TMB) assay to quantita-
tively assess liver heme content, we found that Hfe/ mouse
liver lysate had 9-fold more heme than lysate from wild-type
livers (3.71 ± 0.4 nmol/mg protein versus 0.41 ± 0.12 nmol/mg
protein) (Figure 1B). We next assessed liver p53 protein content
and found that total Hfe/ liver lysates had significantly lower
endogenous p53 protein levels than wild-type livers (Figure 1C).
The level of p53 protein in primary hepatocytes fromHfe/mice
was also markedly lower than that in wild-type hepatocytes (Fig-
ure S1A). Moreover, compared to wild-type mice on a normal
diet, wild-type mice fed with a high iron diet had considerably
lower p53 protein levels (Figures 1D and 1E). Thus, iron overload
inmice, due to either a genetic perturbation of ironmetabolism or
a high iron diet, correlates with a significant reduction in p53
protein levels.
Hemin Directly Modulates p53 Stability without
Involving the Transcription Factor Hypoxia-Inducible
Factor 1 a
Wenext demonstrated that hemin treatment could downregulate
endogenous p53 protein in both mouse primary hepatocytes
and human hepatocarcinoma HepG2 cells in a hemin dose-
dependent manner (Figures S1B and 2A). Treatment with ferric
ammonium citrate (FAC; 100 mg/ml, 6 hr) apparently also
reduced p53 levels (Figure S1C). The p53 reduction seemed to
be independent of transcription because hemin also decreased
exogenously expressed p53 protein in the presence of the
protein translation inhibitor cycloheximide (CHX) (Figure 2B).
Furthermore, inhibition of heme biogenesis in HepG2 cells with
succinylacetone, a 5-aminolevulinate synthase (ALAS) inhibitor,
led to increased p53 (Figure 2C). This effect could be reversed
by hemin, but not FAC, suggesting that hemin may directly
downregulate endogenous p53 protein.
Treatment of HepG2 cells with the iron chelator deferoxamine
(DFO) significantly increased the steady-state level of endoge-
nous p53 protein in a manner independent of protein synthesis
(Figures 2D and 2E). The HepG2 cells were cultured in normal
media that contained serum iron, and hemin could reverse the
stabilizing effect of DFO treatment on endogenous p53 protein
(Figure 2D). When the cells were adapted to serum- and
iron-free media (VP-SFM), DFO itself could no longer stabilize
endogenous p53 protein, but hemin treatment still efficiently
destabilized p53 protein in a manner that could not be reversed
by iron chelation (Figure 2F). This strongly suggests that hemin
directly modulates the stability of endogenous p53 protein,
without involving iron ions that may be released from heme-
oxygenase-catabolized heme.
A previous study has shown that DFO may promote p53 tran-
scription through stabilizing hypoxia-inducible factor 1 a (HIF-1a)
(An et al., 1998). To test if we are observing such a phenomena,
we probed for p53 protein levels in human renal cancer 786-OCell Reports 7, 180–193, April 10, 2014 ª2014 The Authors 181
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Figure 1. Tumor Suppressor p53 Protein Is
Downregulated in Iron Excess
(A) Perls’ Prussian Blue staining ofHfe+/+ andHfe/
mouse liver sections (representative sections
shown). Scale bars represent 100 mm.
(B–E) Homeostatic levels of iron, heme, and
endogenous p53 protein in the livers of Hfe/ and
Hfe+/+ mice (B and C) or Hfe+/+ mice fed on a normal
or high-iron diet were measured (D and E). Iron or
heme content was determined using an unsaturated
iron-binding capacity or TMB assay, respectively
(B and D), and protein levels were measured by
immunoblotting (IB) with the indicated antibodies
(C and E). In (B) and (D), iron or heme levels in the
livers of wild-type mice fed a normal diet were set to
100%. Protein levels were normalized by setting the
static endogenous p53 levels in the livers of Hfe+/+
mice (C) and normal-diet mice (E) as 100%.
Comparative quantification of band intensities was
performed with ImageJ. Bar graphs are shown as
mean ± SEM (n = 3). *p < 0.05.cells that are null in both vHL (von Hippel-Lindau tumor suppres-
sor) and HIF-1a (Kaelin, 2004) and found that hemin destabilized
endogenous p53 protein and iron chelation stabilized p53
protein in a hemin treatment-reversible manner (Figure 2G).
These data collectively suggested that the effect of hemin or
iron chelation on the homeostasis of p53 protein involves
posttranslational mechanisms that do not significantly involve
the transcription factor HIF-1a.
Tumor Suppressor p53 Protein Directly Binds to Heme
In Vitro
An examination of the p53 amino acid sequences across several
species revealed that all of them bear three putative heme regu-
latory motifs (HRMs), consisting of Cys-Pro (CP) sequences that
occur in a subset of heme-binding proteins (Zhang and Guar-182 Cell Reports 7, 180–193, April 10, 2014 ª2014 The Authorsente, 1995) (Figures 3A and 3B). A TMB
assay verified that the His6-tagged p53
protein, freshly purified from bacteria, con-
tained heme (Figure 3C), whereas a simi-
larly tagged human Ub did not (data not
shown). Matrix-assisted laser desorption-
ionization (MALDI) mass spectra analysis
further confirmed that free heme (m/z 616
± 2Da) was associatedwith freshly purified
p53 protein (Figure S2A). In addition,
hemin immobilized on agarose beads, but
not agarose beads alone, recovered
endogenous mouse and human p53 pro-
teins from multiple cell types (Figure S2C).
However, p53 protein fractions lost heme
during dialysis (Figure S2E), suggesting
that heme might associate with p53 non-
covalently. p53 proteins, as well as ATE1,
bound to heme with a dissociation con-
stant (KD) in the low micromolar range
and lost their associated heme at a rate
faster than BSA, whose affinity to heme isat nanomolar range (Figure S2E). Under the same conditions,
lysozyme, which does not bind to heme, readily lost heme
even more quickly (Figure S2E). The rates of heme loss from
the heme-binding proteins were thus conversely related to how
tightly the proteins might bind to heme.
We next incubated heme with purified human p53 protein (see
Figure 3D for purity of the protein) to reconstitute the heme-p53
complex in vitro, using gel filtration in size-exclusion chromatog-
raphy (SEC) to remove unbound heme. UV-visible (UV-Vis)
spectra analysis of the recovered heme-p53 complexes mani-
fested a Soret peak at 413 nm, diagnostic of heme-protein
binding (Ponka, 1999) (Figure 3D). The TMB assay again
confirmed the presence of heme in the post-SEC heme-p53
complexes. A tryptophan fluorescence quenching assay further
indicated that the p53 bound to heme at a 1:1 molecular ratio,
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Figure 2. Hemin Destabilizes p53 Protein
Independently of HIF-1a
Immunoblots (IB) were probed with the indicated
antibodies.
(A) HepG2 cells were treatedwith hemin at indicated
concentrations for 8 hr.
(B) HepG2 cells transiently expressing HA-tagged
human p53 were pretreated with CHX (25 mg/ml) for
6 hr before hemin addition (15 mM, 8 hr).
(C) HepG2 cells were cultured in the absence (Ctrl)
or presence of succinylacetone (1 mM, 24 hr), with
or without hemin (10 mM, 6 hr) or FAC (100 mg/ml,
6 hr) treatment.
(D) HCT116 p53+/+ cells were treated with or without
DFO (100 mM, 24 hr) and with or without hemin
(10 mM, 8 hr).
(E) HepG2 cells were pretreated with or without DFO
(100 mM, 24 hr), then subjected to CHX (25 mg/ml)
treatment for the indicated times. Relative amounts
of remaining endogenous p53 protein (%) were
plotted against the indicated time course (lower
panel).
(F) HepG2 cells, adapted to serum-free growth
conditions by growing in VP-SFM (Invitrogen) for
8 hr, were treated with DFO (100 mM, 24 hr), hemin
(10 mM, 24 hr), or both.
(G) HIF-1a and vHL null 786-O cells were
treated with DFO (100 mM, 24 hr), hemin (10 mM,
8 hr), or both.with a KD of 1.20 mM (Figure 3E), suggesting a fairly strong
interaction between heme and p53 protein. Consistent results
were obtained by surface plasmon resonance analysis
(Figure S2D).
A previous study has demonstrated that hemoglobin, NPAS2,
E75, or other heme-binding proteins gain gas-sensing properties
only upon complexing with heme (Reinking et al., 2005). To test
whether heme-p53 complexes also respond to gas, the solution
containing the preformed hemin-p53 complex was degassed
and Argon purged to maximally remove dissolved oxygen (O2).
Subsequent addition of dithionite solution and carbon monoxide
(CO) infusion led to substantial blue shifts in the UV-Vis spectra:
with a lmax of Soret peak I shifting from 423 to 414 nm and a lmax
of Soret peak II from 475 to 535 nm (Figure 3F). Interestingly,
nitric oxide (NO) infusion induced distinct changes in the UV
spectra of p53-heme, whereas O2 infusion caused little or no
change. These data suggest that the heme-binding property of
p53 protein might confer gas responsiveness to p53, with
specificity comparable to that observed with many other
heme-binding proteins (Dioum et al., 2002; Reinking et al., 2005).Cell Reports 7, 180–The C-Terminal HRM in p53 Protein
Is Required for Heme Binding
To further dissect the interaction between
p53 and heme, we examined the three
HRM-like CP motifs that are conserved
in p53 (Figures 3A and 3B). Among them,
the C-terminal CP motif (Cys277Pro278 in
human p53) resides within a redox-sensi-
tive CXC motif at the C terminus of the
highly conserved DNA-binding domain(DBD) of p53 protein (Cho et al., 1994; Friedman et al., 1993;
Hainaut and Milner, 1993) (Figure 3B). We performed alanine
(Ala) substitutions at Cys141-Pro142, Cys176-Pro177, and/or
Cys277-Pro278 to generate single or joint mutants of the CP
motifs in p53. Both the TMB assay and UV spectra analyses
of postgel filtration heme-protein complexes found no signifi-
cant differences between the wild-type and mutant p53s,
regardless of single or joint mutation in any of the three CP
motifs (data not shown). Interestingly, Ala substitution of the
Cys residues in the C275AC277P stretch manifested in substan-
tially lower heme affinity than wild-type p53 (Figures 4A and 4B).
A fluorescence quenching assay further indicated that the
corresponding KD value for p53C275, 277A-heme binding rose
to 15.7 mM, over 10-fold higher than that of wild-type p53
(KD 1.2 mM) (Figure 3E). Meanwhile, mass spectra analysis
showed that little or no heme could be detected in association
with p53C275, 277A, which was expressed and freshly recovered
from E. coli (Figure S2B). This again suggested a weaker bind-
ing of the p53C275, 277A mutant to heme that is naturally available
in E. coli culture. Altogether, we have identified Cys275 and193, April 10, 2014 ª2014 The Authors 183
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Figure 3. Tumor Suppressor p53 Protein Directly Interacts with Heme
(A) Schematic domain structure of human p53 protein, with putative HRMs marked by their amino acid sequences. TAD, transcription activation domain; TET,
tetramerization domain.
(B) Sequence alignment of the CACP motif in p53 proteins across species.
(C) Gel filtration of p53 protein. BSA was used as a positive control of heme binding and lysozyme as the negative control.
(D) UV-Vis spectrum of heme-p53 complexes (after gel filtration). Inset shows the purity of the p53 protein.
(E) A tryptophan fluorescence quenching assay of hemin with wild-type and mutant p53 determined that heme associates with wild-type human p53 protein at a
KD of 1.20 mM and with p53C275,277A at a KD of 15.70 mM.
(F) UV-Vis spectra analyseswere performedwith p53-heme complexes before (red line) and after infusion of CO. Arrow indicates the spectral shift upon infusion of
increasing CO until saturation (cyan line). Inset panel zooms in on the 450–625 nm range.
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Figure 4. Heme Interacts with Tumor Suppressor p53 through Its C275AC277P Motif and Interferes with p53-DNA Interactions
(A and B) Recombinant wild-type or p53C275,277A mutant protein (10 mM) was incubated with hemin (50 mM) on ice, followed by gel filtration and TMB
assay (Pierce).
(C) A close-up view of the C275 and C277 residues of human p53 in the p53 core domain-DNA (Cho et al., 1994) (derived from PDB 1TSR).
(D) EMSA of the indicated hemin amounts, p53 protein, and double-stranded DNA probes containing p53RE consensus sequences. Band designations are free
DNA (F) and bound DNA (B; p53-DNA complex).
(E) HCT116 p53/ cells transiently expressing HA-tagged wild-type p53 were cotransfected with indicated luciferase reporter plasmids, then treated with or
without hemin (10 mM, 6 hr). Error bars indicate ± SEM (n = 3). **p < 0.01.Cys277 in human p53 protein as two key residues required
for p53-heme interaction.
Heme Interferes with p53-DNA Interaction In Vitro
and In Vivo
Interestingly, sporadic mutations at Cys275 and Cys277 were
found in human patients with cancer (Frebourg et al., 1995)and caused a loss of expression of a p53 transcriptional reporter
(Figure S3).We next sought to investigate whether heme-binding
would directly affect p53-DNA interactions by assaying the
impact of hemin on an electrophoretic mobility shift assay
(EMSA) of recombinant p53 protein and double-stranded DNA
probes containing the consensus p53-responsive element
(p53RE) (Jayaraman and Prives, 1995). Hemin interfered withCell Reports 7, 180–193, April 10, 2014 ª2014 The Authors 185
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Figure 5. Heme Destabilizes p53 Protein through Triggering Its Nuclear Export
Immunoblots (IB) were probed with the indicated antibodies.
(A) HepG2 cells were treated with or without hemin (10 mM, 10 hr) in the presence of CHX (25 mg/ml) for the indicated times.
(B) HepG2 cells transiently expressing His6-tagged Ub (His6-Ubi) were treated with hemin (10 mM), MG132 (10 mM), or both for 6 hr. Endogenous p53 protein was
immunoprecipitated with anti-p53 in modified RIPA buffer, followed by immunoblotting with anti-His6.
(legend continued on next page)
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p53-p53RE interactions in a dose-dependent manner, with
20 mM hemin almost completely abolishing the gel shift (Fig-
ure 4D). Hemin, when applied at 10 mM for 6 hr, furthermore
appeared to significantly interfere with p53-mediated transcrip-
tion of luciferase reporters under the control of p21 or Bax
promoter-derived p53RE sequences (Figure 4E). Immunoblot-
ting indicated that hemin treatment also led to a reduced expres-
sion of endogenous p21 and Bax proteins in a p53-dependent
manner (Figure 6B), showing that heme-p53 interactions may
potentially play a biological role.
Heme Destabilizes p53 Protein Mainly through the
Ub-Proteasome System
Becausewe found that the homeostatic level of endogenous p53
protein decreased in a hemin dose-dependent manner (Figures
2A and S1B), we further investigated the potential functional
consequences of the heme-p53 interaction in a CHX-chase
experiment to examine the stability of endogenous p53 in cells
with or without hemin treatment. To this end, the hepatoma
cell line HepG2 was first adapted to growth in VP-SFM (8 hr)
and subsequently treated with hemin at concentrations compa-
rable to that in previous work (Hu et al., 2008; Wu et al., 2009). In
a 3 hr time course experiment, the p53 protein half-life in hemin-
treated cells was about 2-fold shorter than that in untreated
controls, indicating that hemin treatment accelerated the degra-
dation of p53 in cells (Figures 5A and S4). In addition, hemin-
triggered destabilization of p53 protein was concurrent with
increased p53 ubiquitylation and could be efficiently blocked
by the proteasome inhibitor MG132, but not by the autophagy
inhibitor bafilomycin A (BAF), suggesting that hemin-induced
p53 degradation occurs mainly through the Ub-proteasome sys-
tem (Figures 5B and S4).
Heme Triggers Nuclear Export of p53 Protein Involving
Its C-Terminal Nuclear Export Sequence
Subcellular localization of p53 protein is critical for regulating its
stability because degradation of p53 protein largely takes place
in the cytosol (Brooks and Gu, 2011; Liu et al., 2011; Vousden
and Prives, 2009). Fractionation experiments indicated that
hemin treatment led to p53 protein redistribution in the cell: the
level of p53 protein dropped in the nuclear fraction with a
concomitant increase in the cytosolic fraction (Figure 5C). Treat-
ment with the proteasome inhibitor MG132 seemed to result in
p53 protein accumulation in both cytosolic and nuclear fractions,
with or without hemin treatment. Immunofluorescence micro-
scopy directly showed that hemin treatment significantly(C) Cytoplasmic and nuclear fractions were prepared from HepG2 cells treated
references. Where indicated, 10 mM MG132 was added.
(D) Immunofluorescence microscopy of p53 in HepG2 cells with or without hemi
(E) Hep2G cells were treated with or without LMB (5 ng/ml) and hemin (10 mM).
(F and G) Both GFP-p53L348, 350A (nuclear export sequence mutant) and GFP
hemin-induced nuclear export (10 mM, 6 hr). The percentages of cells with predom
a field of view were quantified in (G). The scale bars represent 10 mm. Data are s
(H) HepG2 cells expressing HA-tagged wild-type p53 or HA-tagged p53L348,350A m
for the indicated times.
(I) HepG2 cells expressing HA-tagged wild-type p53 or HA-tagged p53 C275, 277A
for the indicated times.promoted nuclear export of endogenous or C-terminally GFP-
tagged p53 protein in HepG2 cells (Figures 5D and 5G). When
hemin was applied to cells pretreated with leptomycin B
(LMB), a nuclear export inhibitor that alkylates and inhibits
chromosomal region maintenance (CRM1)/exportin 1 (XPO1),
hemin-triggered nuclear export and degradation of p53 were
both blocked (Figures 5E and S5A), suggesting that hemin-
triggered nuclear export of p53 is an upstream event required
for heme-mediated p53 destabilization.
Because mammalian p53 proteins contain both N- and
C-terminal nuclear export signals (NESs) (Stommel et al.,
1999), we introduced amino acid mutations in each NES to
determine which NES may be involved in hemin-triggered
nuclear export. Although mutations in the N-terminal p53 NES
did not affect hemin-induced p53 export in HepG2 cells (data
not shown), p53L348,350A, which contains Leu
348Ala and
Leu350Ala substitutions that inactivate the C-terminal NES in
p53, was found to exclusively localize to the nucleus, with or
without hemin treatment (Figure 5F). Consistently, p53L348,350A
was also resistant to hemin-accelerated degradation (Figure 5H),
suggesting that hemin-induced degradation of nuclear p53
protein, if it occurs, contributes little to the hemin-triggered
decrease in total cellular p53 protein. Therefore, the C-terminal
p53 NES may play a critical role in heme-induced nuclear export
of p53. Potentially, heme binding to p53 may unmask the
C-terminal p53 NES and promote its interaction with CRM1/
XPO1, followed by nuclear export, ubiquitylation, and protea-
some-dependent p53 degradation in the cytosol. In further
support of this model, glutathione S-transferase (GST)-tagged
CRM1 pulled down preconstituted p53-heme complexes more
efficiently than p53 protein alone (Figure S5B). In addition,
p53C275, 277A, which harbors mutations that disrupt heme bind-
ing, was found to be resistant to hemin-induced nuclear export
and degradation (Figures 5F and 5I), suggesting that the p53-
heme interaction is required for heme-triggered p53 nuclear
export and cytosolic degradation.
IronDeprivation SuppressesGrowth andTumorigenicity
of Human Colon Carcinoma Cells in a p53-Depedent
Manner
The modulation of iron/heme metabolism has emerged as a
major strategy for cancer chemotherapy (Ashcroft et al., 2000;
Buss et al., 2004; Liang and Richardson, 2003; Turner et al.,
2005). In iron deprivation-based chemotherapy, iron chelators
such as DFO suppress the proliferation ofmultiple types of tumor
cells, arrest the cells in the G1/S phase of the cell cycle, andwith or without hemin (10 mM, 6 hr), using actin and lamin B as respective
n (10 mM, 5 hr).
-p53C275,277A (the p53 mutant impaired in heme binding) were resistant to
inantly nuclear localization of p53 over the total number of GFP-positive cells in
hown with mean ± SEM (n = 5). **p < 0.01.
utant were treated with hemin (10 mM, 6 hr) in the presence of CHX (25 mg/ml)
mutant were treated with hemin (10 mM, 6 hr) in the presence of CHX (25 mg/ml)
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Figure 6. Iron Deprivation Suppresses Multiple Human Tumors in a p53-Dependent Manner
(A) Flow cytometry analyses of HCT116 p53+/+ or HCT116 p53/ cells treatedwith or without DFO (100 mM, 24 hr), FAC (100 mg/ml, 8 hr), or hemin (10 mM, 8 hr) as
indicated. Data are represented as mean ± SEM (n = 3). *p < 0.05.
(B) Hemin treatment (10 mM, 6 hr) destabilized p53 and downregulated endogenous p21 and Bax expression in a p53-dependent manner.
(C) Nude mice were subcutaneously seeded with HCT116 p53+/+ and HCT116 p53/ cells and treated with DFO (500 mg/kg/d over 6 consecutive days). Tumor
masses were dissected from treated mice and weighed. Data are represented as mean ± SEM (n = 4). **p < 0.01.
(legend continued on next page)
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induce apoptosis. Increased levels of p53 protein, and also p63
and p73, were commonly observed upon iron chelation (Ba et al.,
2011), but the underlying mechanisms remain unknown.
A past study has indicated that DFO induces G1/S cell-cycle
arrest in both HCT116 p53+/+ and HCT116 p53/ colorectal
carcinoma cell lines (Bunz et al., 1998). We applied hemin or
iron to DFO-treated cells and only observed rescue from DFO-
induced G1/S arrest in HCT116 p53+/+ cells (Figure 6A). Consis-
tent with the hemin-accelerated degradation of p53, addition of
heminwas also found to downregulate steady-state levels of p21
and Bax in HCT116 p53+/+ cells, but not in the isogenic p53/
cells (Figure 6B). Altogether, with our findings that DFO treat-
ment led to p53 protein stabilization in a hemin-reversible
manner (Figures 2D and 2G), p53 may mediate at least a portion
of the cellular responses to iron or heme metabolism perturba-
tions, likely through modulating the transcription factor activity
of p53 and lowering the availability of total p53 protein.
To more directly assess the roles that p53 might play in iron
deprivation-based chemotherapy, a tumorigenicity assay was
performed with nude mice that bore either HCT116 p53+/+ or
p53/ cells. Both p53+/+ and p53/ HCT116 cells formed
tumors in nude mice with comparable efficiency (Figures 6C
and S6). DFO administration (500 mg/kg/d) was found to sup-
press the growth of tumors formed by p53+/+ HCT116 cells by
over 80%. Strikingly, the growth of p53/ HCT116-derived tu-
mors only decreased by 12% in response to DFO, strongly sug-
gesting that stabilization of p53 might underlie the selective tu-
mor-suppressing effects of iron deprivation in these cells.
Finally, we tested for the tumor-suppressing effects of DFO on
six immortal human cancer cell lines that are either p53 null (NCI-
H1299, SaoS2, and CRL-5807) or bearing sequence-confirmed
wild-type p53 (U2OS, ACHN, and NCI-H460). DFO treatment
strongly suppressed proliferation of cancer cell lines expressing
wild-type p53 in a DFO dose-dependent manner (over 50%–
70% inhibition at 100 mM DFO; approximately 70%–80% inhibi-
tion at 400 mMDFO). In contrast, similarly treated p53 null cancer
cell lines exhibited no more than 30% inhibition of cell prolifera-
tion (Figure 6D). Thus, the presence of endogenous wild-type
p53 appears to critically underlie the tumor-suppressing effects
of iron deprivation on the cell types examined in this study.
DISCUSSION
Iron is essential for the normal functions of cells, but excess iron
has been a strong risk factor for a variety of human malig-
nancies, with mechanisms yet unclear (Torti and Torti, 2013).
Given the critical roles that tumor suppressor p53 protein plays
in regulating tumorigenesis, cell death, drug responses, as well
as cancer cell metabolism (Baker et al., 1989; Maddocks and
Vousden, 2011; Tavana and Gu, 2013; Vogelstein et al., 2000),
we set out to examine homeostatic levels of p53 protein upon
iron excess or deprivation. We found that p53 protein levels in
the livers and primary hepatocytes of Hfe/ mice were signifi-(D) p53 null (NCI-H1299, SaoS2, and CRL-5807) and wild-type p53 (U2OS, AC
at a density of 2 3 103 cells per well and subjected to DFO treatment at ind
1 hr, and Hoechst-positive cells were counted in fluorescence images. The data
**p < 0.01.cantly lower than that in wild-type mice (Figures 1A–1C and
S1A). A similar phenomenon was observed in wild-type mice
fed a high iron diet (Figures 1D and 1E). These data strongly sug-
gest that iron excess, a condition of heme overload, leads to
downregulation of endogenous p53. The finding that heme
directly binds to p53 protein with a micromolar KD further con-
solidates the direct link between iron metabolism and p53
signaling (Figure 3). The gas-sensing property of the in vitro
p53-heme complex (Figures 3F and S2F) has opened the possi-
bility that p53, like other transcription factors, E75 and NPAS2,
may at least partially mediate cellular responses to gas signaling
if p53 protein indeed binds to heme under normal physio-
logical conditions. Whether this is indeed the case warrants
further study.
Our CHX-chase experiments have demonstrated that iron/
heme excess downregulates homeostatic levels of p53 protein
mainly through accelerating p53 protein degradation. Hemin
likely unmasks the C-terminal NES to allow p53 interaction
with CRM1/XPO1, nuclear export, and subsequent cytosolic
degradation through the Ub-proteasome system (Figures 4
and 5). Mapping out C275AC277P as the heme-interacting region
in p53 has provided further molecular detail of the p53-heme
interaction (Figure 4). Because C275AC277P resides near the C
terminus of the DBD of p53, we also tested and discovered
that heme binding interferes with p53-DNA interactions, thus
affecting the transcription factor activity of p53 (Figure 4). In
particular, the transcription of p21 and Bax, two p53 target
genes, was found to be attenuated in cells upon hemin treatment
(Figure 6B). Taken together, iron and heme excess may nega-
tively regulate p53 signaling in the afflicted cells through both
destabilizing p53 protein and interfering with its binding to the
target DNA. Our findings may thus provide mechanistic insight
into iron excess-associated tumorigenesis.
Finally, our experiments with HCT116 p53+/+ and p53/ cells
strongly suggested that iron deprivation induces cell-cycle arrest
and suppresses tumor formation and cell proliferation in a p53-
dependent manner (Figures 6A, 6C, 6D, and S6). As such, the
presence of wild-type p53 signaling in tumors might critically
affect the clinical outcome of iron deprivation-based therapy.
Future clinical studies of iron deprivation-based chemotherapy
may choose to monitor the p53 status of patient tumors to
determine whether only tumors with wild-type p53 signaling
can benefit.
Previous studies have reported on p53-independent tumor-
suppressing activities of putative iron chelators (Abeysinghe
et al., 2001; Whitnall et al., 2006). Tachpyridine, first synthesized
as a potent iron chelator, was reported to induce apoptosis in
cultured cancer cells in a manner nonresponsive to p53 overex-
pression. Tachpyridine induced p53 protein accumulation but
did not induce downstream p21 expression. Interestingly, a later
study revealed that tachpyridine also chelates zinc ion as effi-
ciently as iron (Zhao et al., 2004) and, thus, potentially deprives
p53 of zinc ion, which is necessary for p53’s DNA-bindingHN, and NCI-H460) human cancer cell lines were seeded in a 96-well plate
icated concentrations for 72 hr. Cells were stained with Hoechst 33258 for
represent at least three independent experiments. Error bars indicate ± SEM.
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activities. Thus, tachpyridine may prevent p21 upregulation
despite inducing p53 upregulation, explaining the lack of evi-
dence for p53 pathway involvement in tachpyridine’s tumor-sup-
pressing activities. Further study is warranted to investigate the
mechanisms underlying reports of p53-independent antitumor
effects by other structurally unrelated iron chelators (Whitnall
et al., 2006). These previous findings, together with our findings,
demonstrate that putative iron chelators, with potentially com-
plex actions perturbing several different pathways, may corre-
late with iron chelation and p53 upregulation to varying extents.
Potentially, cancers, with varying genetic backgrounds within
patient populations and across cancer types, may also respond
differently to iron chelation depending on the functionality of their
individual p53 signaling networks.
The other p53 family proteins, p63 and p73, are upregulated
in cell models of iron deprivation-based chemotherapy (Ba
et al., 2011) and contain the same CXCP motif we identified
to be essential for heme-p53 binding (Figure S7A). Indeed,
hemin-agarose affinity chromatography efficiently recovered
p63 and p73 proteins overexpressed in HepG2 cells (Fig-
ure S7B). Remarkably, hemin also destabilized the p63 and
p73 proteins (Figure S7C), reminiscent of our previous observa-
tions with p53 protein. Thus, the p53 protein family contains the
heme-binding CXCP motif, binds to heme, and undergoes
accelerated degradation upon hemin treatment. Conceivably,
heme-induced nuclear export and destabilization of p53 family
proteins, along with ensuing functional changes, may occur at
the organism level. Iron overload and accumulation of heme in
afflicted cells or tissues may eventually lead to the production
of reactive oxygen species (ROS) and damage intracellular
structures including proteins and DNA (Torti and Torti, 2013),
where normal function of p53, ‘‘the guardian of the genome,’’
could be essential to mitigating these insults and help cell
survival. However, heme-induced nuclear export and destabili-
zation of p53 and other proteins might exacerbate the insults,
thus contributing to the pathogenesis of iron excess-associ-
ated disorders such as hemochromatosis, e.g., iron excess-
promoted tumorigenesis.
In sum, our findings have revealed a direct link between iron/
heme homeostasis and the control of the stability, localization,
and function of p53 (and potentially the p53 protein family).
Therefore, we have not only shed insight on the mechanisms
underlying tumorigenesis associated with iron/heme excess
but also provided a molecular basis for iron deprivation-based
chemotherapy. It would be interesting to explore whether
heme-accelerated degradation of p53 might play a role in other
pathogenic features of hemochromatosis.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
To express human p53 or its mutants bearing Cys to Ala and Pro to Ala
substitutions in one or multiple CP motifs, cDNA encoding wild-type or
mutant human p53 was cloned into the pHUE vector to obtain proteins with
histidine 3 6 (His6)-Ub and FLAG tags at their N and C terminus, respectively.
Proteins expressed in E. coliwere purified, and the N-terminal His6-Ub tag was
removed through Usp2CC cleavage as previously described (Hu et al., 2005).
GST-tagged CRM1 was constructed and purified following procedures
described before (Wu et al., 2013).190 Cell Reports 7, 180–193, April 10, 2014 ª2014 The AuthorsGel Filtration, Spectroscopy Analysis, and TMB Assay
of Hemin-Protein Complexes
Purified FLAG-tagged human p53 (10 mM) or its mutants (10 mM), chicken egg
white lysozyme (10 mM) or BSA, were incubated with hemin (50 mM) in binding
buffer (20 mM HEPES [pH 7.4], 10% glycerol, and150 mM NaCl) for 10 min on
ice, then passed through pre-equilibrated NAP-5 columns (GE Healthcare) to
remove the unbound hemin as previously described (Hu et al., 2008). UV-Vis
spectra analyses of heme only or the heme-protein complexes were carried
out on Varian or Hitachi U-3010 spectrophotometers. Hemin content was
determined (in triplicate) using the TMB-based assay (Pierce), according to
the manufacturer’s instructions.
Animal Manipulations
Hfe knockout mice (Hfe/) of C57/Bl/6-129/Ola genetic background were a
kind gift from Dr. Nancy C. Andrews (Departments of Medicine and Pediatrics,
Harvard Medical School, Boston). All animals were handled according to
protocols reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC).
Measurements of Iron and HemeContents inMouse Liver Lysates or
Primary Hepatocytes
Experimental iron overload was achieved by feeding 4-week-old B6 wild-type
male mice a regular diet supplemented with 8.3 g/kg carbonyl iron (Sigma-
Aldrich) for 3 weeks. Liver samples were weighed, and iron content was
measured using the unsaturated iron-binding capacity assay as previously
described by Ba et al. (2011). Liver samples containing equal amounts of total
protein (30 mg) were subjected to the TMB assay to determine hemin content.
Isolation of primary hepatocytes from Hfe+/+ and Hfe/ mice was carried out
as described before (Wang et al., 2009). Hemin contents were measured
(in triplicate) using the TMB-based assay for hepatocytes from Hfe +/+ versus
Hfe / mouse littermates.
Preparation of Hemin Solution and Hemin Treatment of Mammalian
Cells
Stock hemin (Fe3+ heme) solution was freshly prepared in 0.1 N NaOH for each
experiment. The hemin concentration was determined using the extinction
coefficient ε385 = 5.84 3 10
4 M(1)cm(1). Mammalian cells were adapted to
serum-free growth conditions by growing them in VP-SFM (Invitrogen) as
described before (Hu et al., 2008). For cell-based experiments, hemin
(freshly prepared in DMSO) at indicated concentrations was added to cells
(80%–90%confluence) in VP-SFM (serum-free) medium,with little cytotoxicity
observed for the first 12 hr.
Gas-Sensing Assay
The p53 proteins in stock solution were exchanged into the binding buffer
(20 mM HEPES, 10% glycerol, and 150 mM NaCl [pH 7.4]) and preserved at
reduced status by adding Immobilized TCEP (Tris-20-carboxyethyl-phosphine)
Disulfide Reducing Gel (Thermo Scientific). Immediately before use, the TCEP
gels were pelleted to give clear p53 protein solutions. p53 proteins (10 mM)
were then incubated with 50 mM hemin in binding buffer on ice for 15 min
and desalted using NAP-5 columns to remove free hemin. The solutions
(0.5 ml) containing recovered p53-hemin complexes were kept in sealed, air-
tight cuvettes (VWR) on ice, followed by vacuuming and purging with argon
for over 30 min to remove residual oxygen dissolved in the solution. Dithionate
(at a final concentration of 1.0mM in binding buffer) was injected to reduce iron
in hemin from the Fe3+ to Fe2+ status. Balloons inflated with CO (Sigma-
Aldrich; R99.0%), NO (Sigma-Aldrich; 98.5% passed through 1 N KOH), or
O2 (Sigma-Aldrich;R99.6%) were attached to the cuvettes with long needles
inserted into the solutions. UV-Vis spectra were recorded at 1.5 min intervals
until no shifts were observed, indicating the maximal formation of p53-heme-
gas complexes.
Luciferase Reporter Assay
HCT116 p53/ cells expressing indicated geneswere seeded in 24-well plates
and transfected with the luciferase reporter plasmids. Luciferase reporter
assays were carried out using a dual luciferase assay kit (Promega). Results
were obtained from at least three independent experiments (each in triplicate).
EMSA
EMSA was performed as described before by Jayaraman and Prives (1995)
with slight modifications. The double-stranded DNA probes contained the
consensus p53RE sequence (50-AGG CAT GTC TAG GCA TGT CT-30 and
50-AGA CAT GCC TAG ACA TGC CT-30). The probes were labeled with 32P
at the 30 end with T4 ligase (New England Biolabs). Recombinant human p53
protein (4 mM) was then incubated with hemin at increasing concentrations
on ice for 30 min to allow for protein-hemin complex formation. After 30 min
incubation on ice, the reaction mixtures were subjected to 6% PAGE analysis,
resolving the DNA-protein complexes from the free probes. Gels were then
dried and exposed to a phosphorimager (Kodak) before scanning on a FLA
9000 Fuji scanner.
Tryptophan Fluorescence Quenching Assay
Fluorescence measurements were performed at room temperature (23C)
using a Cary Eclipse spectrofluorometer (Varian) as described before (Hu
et al., 2008) with slight modifications.
Tumorigenicity Assay
Female nudemice (Bi-kai Biotech) aged 5weeks oldwere injectedwith 13 106
HCT116 p53+/+ or HCT116 p53/ cells suspended in Matrigel (BD Biosci-
ences) as described before by Fasano et al. (1984). Two days after tumor
cell seeding, mice bearing evident tumors were randomly divided into control
and DFO treatment groups (four mice per group). DFO was dissolved in water
and injected into tumors at a dose of 500 mg/kg/d over 6 consecutive days.
Animals were euthanized with carbon dioxide, tumor masses were isolated,
and tumor weight was measured.
Ubiquitylation Assays
HepG2 cells transfected with His6-tagged Ub plasmids were treated with
hemin (10 mM), MG132 (10 mM), or both for 6 hr. Cells were lysed, and a protein
ubiquitylation assay was carried out as described previously with slight
modifications (Lee et al., 2008).
Flow Cytometry and Fluorescence Microscopy
All procedures were carried out as described before by Pack et al. (2008), with
more details in Supplemental Information.
Multiple Sequence Alignments and Protein Data Bank Coordinates
Protein sequence alignment was performed with Clustal X v.2.0 according to
the provider’s instruction (Larkin et al., 2007). Coordinates of the p53-DNA
complex were extracted from the Protein Data Bank (PDB 1TSR) (Cho et al.,
1994) and visualized on PyMOL (DeLano Scientific).
Statistical Analysis
All values are expressed as mean ± SEM. The two-tailed unpaired Student’s
t test was used to assess the significance of differences between two data
sets, with statistical significance reached when p < 0.05.
Full methods are available in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2014.02.042.
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